

(19) AUSTRALIAN PATENT OFFICE

(54) Title
Test for transmissible spongiform encephalopathies

(51)⁶ International Patent Classification(s)
G01N 33/68 (2006.01)20060101AFI2006010
G01N 33/68 1BHAU
PCT/IE02/00006

(21) Application No: 2002226643 (22) Application Date: 2002 .01 .18

(87) WIPO No: W002/057789

(30) Priority Data

(31) Number	(32) Date	(33) Country
S20010042	2001 .01 .19	IE

(43) Publication Date : 2002 .07 .30
(43) Publication Journal Date : 2003 .02 .13

(71) Applicant(s)
Enfer Technology Limited

(72) Inventor(s)
O'Connor, Michael

(74) Agent/Attorney
Davies Collison Cave, 255 Elizabeth Street, Sydney, NSW, 2000

(56) Related Art
Sambrook et.al. (1989) Molecular Cloning, A Laboratory Manual. 2nd ed. CSH Laboratory Press, USA, pB.20
US 5773572 A (MEE ROGER PAUL ET AL) 30 June 1998
WO 98/35236 (ENFER TECHNOLOGY LTD) 13 August 1998.
WO 91/00333 A1 (HENKEL KGAA) 10 January 1991
EP 0861900 A (ZUERICH ERZIEHUNGSDIREKTION) 2 September

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057789 A3

- (51) International Patent Classification⁷: G01N 33/68
- (21) International Application Number: PCT/IE02/00006
- (22) International Filing Date: 18 January 2002 (18.01.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
S20010042 19 January 2001 (19.01.2001) IE
- (71) Applicant (for all designated States except US): ENFER TECHNOLOGY LIMITED [IE/IE]; Block A, Earlsfort Centre, Earlsfort Terrace, Dublin 2 (IE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): O'CONNOR, Michael [IE/IE]; 11 Chestnut Road, Mount Merrion, County Dublin (IE).
- (74) Agents: GATES, Marie, Christina, Esther et al.; Tomkins & Co., 5 Dartmouth Road, Dublin 6 (IE).
- (81) Designated States (national): AT, AG, AI, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CI, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
with international search report
- (88) Date of publication of the international search report:
13 March 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/057789 A3

(54) Title: TEST FOR TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES

(57) Abstract: A method of detecting transmissible spongiform encephalopathies is described which involves (a) treating a sample of tissue, blood or a blood derivative from a test subject with alcohol and a detergent, (b) adding an agent which degrades normal prion protein (c) adding an agent which denatures abnormal prion protein, (d) adding a prion-specific antibody and (e) detecting binding of the antibody to the sample. Also described is a method of fixing abnormal prion protein to a substrate comprising (a) treating the protein or a sample suspected to contain the abnormal prion protein with alcohol and an anionic detergent and (b) adding a protease, in the presence of the substrate.

Test for Transmissible Spongiform Encephalopathies

The present invention relates to a method of detecting Transmissible Spongiform Encephalopathies, and in particular to a test which can be conducted on
5 living or dead animals or humans to identify TSEs.

Background to the invention

Spongiform Encephalopathies are a group of degenerative neurological diseases.
10 There are a number of examples of Spongiform Encephalopathies including BSE (Bovine Spongiform Encephalopathy), Scrapie, Creutzfeldt-Jacob Disease (CJD) Gerstmann-Straussler--Scheinker Syndrome, Kuru, Transmissible Mink Encephalopathy, Chronic Wasting Disease of Mule Deer, Feline Spongiform Encephalopathies and other Spongiform Encephalopathies found in animals such as elk,
15 naya, greater kudu, gemsbok and tigers. It has also been reported that BSE can be transmitted under laboratory conditions to mice and pigs. This crossing of species barriers by the infective agent has led to increased concern that transfer to humans could occur.

20 Bovine spongiform Encephalopathy (BSE) is a degenerative brain disorder of cattle which is popularly known as "mad cow disease". It has a slow incubation period, up to four or five years with symptoms of progressive degeneration of the mental state in cows include loss of co-ordination and staggering gait, lack of interest in their surroundings, disinterest in feed and water, or unpredictable behaviour, including
25 aggressiveness. Affected cattle show symptoms when they are three to ten years old.

First identified in Great Britain in November 1986, over 100,000 cases have since been recorded there. Post mortems of affected cattle reveal a characteristic pattern of vacuolation in the brain tissue due to destruction of neural cells and the deposition of
30 unusual protein fibres, that give the brain a spongy (spongiform) texture. Similar spongiform diseases have been recognised in humans (for example, Creutzfeldt-Jakob disease or (CJD) for over a century and in sheep (scrapie) for over 200 years. The agent

thought to be responsible for Transmissible Spongiform Encephalopathies is an infective protein known as a prion. The prion is an infective particle comprising protein only and no nucleic acid, the presence of nucleic acid being required in the case of a conventional virus. In Scrapie in particular one protein known as prion protein or PrP^{Sc} has been found to co-purify with infectivity and can produce a Scrapie-like condition in brain cell cultures from other animals, such as hamsters under laboratory conditions. PrP^{Sc} is the only known component of the characteristic protein fibres deposited in the brain tissue of Scrapie-infected sheep. This protein, the PrP^{Sc} appears to undergo a structural modification, whereas the term PrP^C is used in respect of the normal cellular counterpart of PrP^{Sc}. The natural function of PrP^C is not known, but it appears likely that it has an essential structure or functional role in the organism.

Recycled animal tissue, which had been routinely fed to British dairy cows as a protein supplement has been identified as the source of the infection. It is believed that BSE was originally spread from sheep's brains infected with scrapie and that its spread was accidentally accelerated by the ingestion of brain tissue taken from cows that had become infected with BSE. Therefore, the British Government introduced compulsory destruction of suspect animals and their carcasses beginning in 1988. The feeding of animal tissue to cows was banned in Britain in July 1988.

Since the initial report of the disease, consumers have feared that it might be transferable to humans through milk or beef products, particularly since Kuru, a related disease is known to be spread by ritualistic cannibalism among New Guinea tribesmen. In late 1990, consumer concern over the transmission of BSE to humans triggered a collapse in the beef market. A similar scare struck Germany in mid-1994.

In 1996 ten cases of a newly described type of fatal CJD (Variant CJD) were identified. The victims had distinct brain tissue symptoms, were all under the age of 42, and had no hereditary record of the disease. It has been suggested that the victims may have contacted the disease through contact with BSE-infected cattle before the eradication of suspected animals had taken effect. The identification of Variant CJD led

to a dramatic drop in beef consumption in Britain, and the banning of British and in some instances Irish beef imports in various countries worldwide.

Therefore, for both veterinary and economic reasons, there is an urgent need to
5 provide a method for diagnosis and a diagnostic kit to detect infection with BSE, Scrapie, Variant CJD and other related spongiform Encephalopathies, in livestock, animal carcasses and meat generally, as well as in pharmaceuticals and humans.

Object of the invention

10

It is thus an object of the present invention to provide a method of testing animals, pharmaceuticals and humans for the infective agent responsible for TSE. It is also an object to provide a multitissue test system which can be used on both blood or blood derived products and solid tissue. It is a further object that the method be rapid,
15 with the result being available in a matter of hours, and that it should be cheap, reliable and user friendly.

Until this time there has been no method of detecting TSE which could be conducted on blood or blood derivatives. Up to now the only method of determining
20 whether animals were suffering from TSE or human beings were suffering from a related disease was to carry out a pathological post mortem examination of brain tissue. Thus a test which could be tested on blood has the enormous advantage that it can be conducted on living animals or human beings. This gives rise to the possibility that infected animals could be removed from the population and slaughtered, in an attempt to
25 prevent the spread of infection to other animals in the population. It would also mean that infected human beings could be identified, with the possibility that medical treatment could be administered and a possible cure could be found for the disease. The test would also prevent the entry of infected meat into the human food chain, thus reducing the possibility of humans contracting variant CJD or other related diseases
30 which may be transmitted by eating infected meat. It would also restore consumer confidence in meat or meat-derived products, which would be advantageous to both the farming community and the meat industry in general.

It has now surprisingly been found that a test for TSEs can be carried out on blood or blood derived products. The test has the advantage that it can also be carried out on solid tissue samples.

5

Summary of the Invention

According to the present invention there is provided a method of detecting TSE comprising (a) treating a sample of tissue, blood or a blood derivative from a test subject with alcohol and a detergent, (b) adding an agent which degrades normal prion protein (c) adding an agent which denatures abnormal prion protein, (d) adding a prion-specific antibody and (e) detecting binding of the antibody to the sample.

In one embodiment, the invention provides a method of detecting TSE comprising (a) dispensing a sample of tissue, blood or a blood derivative from a test subject onto an inert support and treating the sample with a homogenization buffer comprising alcohol in an amount up to 30% and between 5% and 30% detergent, (b) adding an agent which degrades normal prion protein, (c) adding an agent which denatures abnormal prion protein, (d) adding a prion-specific antibody, and (e) detecting binding of the antibody to the sample.

15
20

The invention also provides a method of fixing abnormal prion protein to a substrate comprising (a) treating the protein or a sample suspected to contain the abnormal prion protein with alcohol and an anionic detergent and (b) adding a protease, in the presence of the substrate.

25

Step (a) may further comprise the addition of a protein, preferably a high molecular weight protein such as bovine serum albumin, ovalbumin, normal serum of animal origin, an albumin substitute such as Prionex (trade mark), derivatives of such or the like. The protein may be formulated in a buffer containing up to 5%, preferably 0.05 to 0.4% protein.

30

2002226643 04 Oct 2006

- 4a -

5 Preferably the alcohol used in step (a) is a C₁ to C₂₄ alcohol such as methanol, ethanol, propanol, butanol, pentanol, hexanol, heptanol, octanol, nonanol, decanol, undecanol, dodecanol, tridecanol, tetradecanol, pentadecanol, cetyl alcohol, heptadecanol, stearyl alcohol, nonadecanol, eicosanol, docasanol, dodecyl alcohol, lauryl alcohol, octadecanol, and derivatives of each, including primary, secondary and tertiary derivatives, or the like. More preferably the alcohol is a C₁ to C₅ alcohol, most preferably methanol/ethanol. The alcohol may be formulated in a buffer containing up to 30% (by weight), preferably 10 to 20% more preferably 8 to 12% alcohol.

10

Preferably the detergent of step (a) is selected from sodium dodecyl sulphate, sarcosyl, lithium dodecyl sulphate, cholic acid, deoxycholic acid, Triton X-100, octanoic acid, Brij (trade mark) 35 solution, N-Cetyl-N,N,N-trimethylammoniumbromide, 5 CHAPS (3-[(cholamidopropyl)-dimethylammonio]-propane-sulphonate), CHAPSO (3-[(cholamidopropyl)-dimethylammonio]-hydroxypropane-sulphonate), Digitonin, nonanoyl-N-methylglucamide, n-Octyl-B-D-glucopyranoside, alkyl sodium sulphate, dioctyl sodium sulfosuccinate, sodium oleate, sodium lauryl sulphate, 1,2,3-Octanetriol, 3-Diethylamino-1 propyne, Chondroitinase ABC (available from Fluka), sodium 10 Ionophore 1 (available from Fluka), and derivatives of each or the like, most preferably sodium dodecyl sulphate. The detergent may be formulated in a buffer containing 5 to 30%, more preferably 10 to 20% detergent. The detergent may be an anionic detergent.

In step (b) the agent which degrades normal prion protein may suitably be a 15 protease, suitably a broad spectrum protease. Preferably the protease is selected from proteinase K, subtilisin Carlsberg, pepsin and derivatives of each or the like. The protease may be formulated in a buffer containing up to 10mg/ml, preferably 0.05mg/ml to 4mg/ml, more preferably 0.2mg/ml to 0.6mg/ml protein.

20 Preferably the agent which denatures abnormal prion protein in step (c) is a denaturing salt solution. Suitably the agent is selected from guanidine, urea, a standard denaturing solution e.g. Merck denaturing solution (commercially available from Merck) and derivatives of each or the like. In a particularly preferred embodiment the denaturing agent may further include up to 0.5M sodium hydroxide. The denaturing salt 25 may be formulated in a buffer containing 0.1 to 10M, preferably 2 to 8M denaturing salt.

The buffer of step (a) (homogenising buffer) may be made up to have a final pH of 5.0 to 11.0, preferably pH 7.0 to 9.0, more preferably pH 7.5 to 8.5. The buffer of step (b) (differential buffer) may be made up to a final pH of 2.0 to 11.0, preferably pH 30 2.0 to 8.5, more preferably 7.5 to 8.5. The buffer of step (c) (assay priming buffer) should have a pH of 1 to 14, more preferably ph 9 to 12, most preferably at least 11.

Preferably, following step (b) the reaction mixture is washed with distilled water or a first wash buffer comprising up to 10%, preferably 4 to 6% buffered solution.

5 The assay priming buffer is allowed to incubate with the reaction mixture for about 5 to 30 minutes, preferably 10 to 20 minutes. Suitably, the mixture is then washed with a second wash buffer having a final pH of 5.0 to 11.0, preferably pH 7.0 to 8.0.

10 The first wash buffer may comprise sodium chloride, calcium chloride, zinc chloride or the like. The second wash buffer may comprise phosphate buffered saline or the like with the optional addition of 0 to 5% Tween 20 or the like.

15 Preferably the blood or tissue sample is dispensed onto a support, suitably a microtitre tray, and may then preferably be subjected to an optional centrifuge step which serves to clarify or "clean up" the samples for further processing.

The prion specific antibody is raised to a prion sequence which is to the 3' side of amino-acid number 60 of the prion sequence.

The prion specific antibody is suitably directed against the prion peptide:-

20

PRION SEQUENCE N-TERM

MVKSHIGSWILVLFVAMWSDVGLCKKRPKPGGGWNTGGSRYPGQ-44
 GSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQP-87
GGGGWGQGGSHSQWNKPSKPPKTNMKHVAGAAAAGAVVGGGLGGY- 131
 25 MLGSAMSSPLIHFGNDYEDRYTRENMYRYPNQVYYRVPDRYSNQQN-177

wherein the single letter amino acid code is as defined herein, as well as derivative and fragments of the sequences, including those that may include D-isomer amino acids as well be understood by those skilled in the art, modification of this sequence by substitution, deletion or insertion of amino acids could result in a peptide with the same
 30 activity.

The blood sample may either be a whole blood sample, or it may be a blood derived sample such as a serum sample or a buffycoat preparation which includes white blood cells and leucocytes. If the test is used on a solid tissue sample a sample of about 0.3g to 1.5g is used.

5

Suitably the blood or tissue sample is homogenised. If the blood sample is gelatinous an enzyme degradation step may be included. The enzyme degradation step may include the addition of DNase, Rnase, a protease or a lipase.

10

The prion specific antibody may be raised to a variety of species - specific prion sequences in any species. The antibody may be for example raised in rabbits, and the immunoassay may involve the use of a secondary antibody, suitably a goat (species) anti-rabbit antibody conjugated with horseradish peroxidase.

15

The detection method is suitably an enhanced chemiluminescence assay, although colourimetric detection, fluorimetric detection or radioimmunoassay detection could also be used.

20

In a particularly preferred embodiment there is provided a test for Transmissible Spongiform Encephalopathies comprising obtaining a sample of blood or a blood derivative or tissue from a test subject, reacting the tissue, blood or blood derivative sample with a prion specific antibody and detecting the binding of the antibody to the sample by standard immunoassay, wherein the tissue, blood or blood derivative sample is mixed prior to addition of the antibody with a first buffer comprising 0 to 30% of C₁ to C₅ alcohol, 5 to 30% sodium dodecyl sulphate, or 5 to 30% sodium dodecyl sulphate and 0 to 5% sarcosyl, and 0 to 5% bovine serum albumin made up to volume in about 0.1 M TRIS/HCL or phosphate buffer, the buffer having a final pH of 7.0 to 9.0.

25

30

Preferably the blood or tissue sample is dispensed onto a support, more preferably an inert plastic support, suitably a microtitre tray, and a second buffer comprising 1 to 10 mg/ml of a broad spectrum protease enzyme in about 0.1 M TRIS/HCL or phosphate buffer with a final pH of 7.5 to 8.5, is added. The buffer is

suitably diluted 1 in 5 to give a working strength of 0.2 mg/ml to 2 mg/ml. The sample is then incubated, preferably for about 10 to 180 mins at about 37 - 70°C, more preferably at 60°C.

5 Following incubation, the support suitably is washed with a volume of a first wash buffer comprising 0 to 10% salt solution. Preferably, a third buffer comprising either 0.5 to 3M guanidine or 2 to 8M urea, and 0.1 to 0.2M sodium hydroxide made up in reverse osmosis distilled water with a pH of at least 11 at room temperature, is added to the support. Suitably, the support and third buffer are allowed to incubate for about
10 15 minutes and are washed with a wash buffer comprising 0.1M phosphate buffered saline and 0.5% Tween 20™.

The sample preparation is then complete and ready for immunoassay.

15 The invention also provides a test for Transmissible Spongiform Encephalopathies comprising obtaining a sample of blood or blood derivative or tissue from a test subject, reacting the tissue, blood or blood derivative sample with a prion specific antibody and detecting the binding of the antibody to the sample by standard immunoassay, wherein the blood or tissue sample is dispensed onto an inert support and
20 incubated with a buffer comprising up to 10 mg/ml, preferably 0.05mg/ml to 4mg/ml, more preferably 0.2mg/ml to 0.6mg/ml, of a broad spectrum protease enzyme in a buffer with a final pH of 2.0 to 11.0, preferably pH 2.0 to 8.5, more preferably 7.5 to 8.5, prior to reaction with the antibody. Preferably the inert support is centrifuged following dispense of the sample and before addition of the protease(differential buffer). The
25 protease may be formulated in a buffer comprising 0.1M TRIS or phosphate.

In one embodiment, the invention provides a test for Transmissible Spongiform Encephalopathies comprising homogenizing a sample of blood or blood derivative or tissue obtained from a test subject in a homogenization buffer comprising alcohol in an amount up
30 to 30% and between 5% and 30% detergent, reacting the tissue, blood or blood derivative sample with a prion specific antibody and detecting the binding of the antibody to the sample by standard immunoassay, wherein the blood or tissue sample is dispensed onto an

2002226643 04 Oct 2006

- 8a -

inert support and incubated with a buffer comprising up to 10 mg/ml of a broad spectrum protease enzyme in a buffer with a final pH of 2.0 to 11.0 prior to reaction with the antibody.

- 5 In a further aspect the invention provides a test for Transmissible Spongiform Encephalopathies comprising obtaining a sample of blood or a blood derivative or tissue from a test subject, reacting the tissue, blood or blood derivative sample with a prion specific antibody and detecting the binding of the antibody to the sample by standard immunoassay, wherein the sample is incubated with a buffer comprising 0.1 to 10M
- 10 denaturing solution, preferably 3 to 6M, more preferably 0.5 to 3M Guanidine (optimal

range 2 to 4M) or 2 to 8M urea (optimal range 4 to 6M), and up to 0.5M, preferably 0.1 to 0.2M sodium hydroxide made up in reverse osmosis distilled water, with a pH of at least 11 at room temperature, prior to reaction with the antibody.

5 In one embodiment, the invention provides a test for Transmissible Spongiform Encephalopathies comprising homogenizing a sample of blood or a blood derivative or tissue obtained from a test subject in a homogenization buffer comprising alcohol in an amount up to 30% and between 5% and 30% detergent, reacting the tissue, blood or blood derivative sample with a prion specific antibody and detecting the binding of the
10 antibody to the sample by standard immunoassay, wherein the sample is incubated with a buffer comprising 0.1 to 10M denaturing solution, preferably 3 to 6M Guanidine or 2 to 8M urea, and up to 0.5M sodium hydroxide made up in reverse osmosis distilled water, with a pH of at least 11 at room temperature, prior to reaction with the antibody.

15 The invention also provides a buffer selected from:

1. 0 to 30% of C₁ to C₂₄ alcohol (optimal range 10 to 20, preferably 8 to 12%) 5 to 30% detergent (optimal range 10 to 20%), and a 0 to 20% protein (optimal range 0.05 to 0.4%) made up to volume in a buffer having a final pH of 5.0 to 11.0 (optimal range 7.5 to 8.5).
2. A buffer comprising of 0.05mg/ml to 4mg/ml (optimal range 0.2mg/ml to 0.6mg/ml) of a protease enzyme in a buffer having a final pH of 2.0 to 11.0 (optimal range 2.0 to 8.5).
3. A buffer comprising 0.1 to 10M denaturing solution (optimal range 2 to 8M).

20

All buffers are produced and supplied by Enfer Scientific Ltd.

Homogenising Buffer:

Ingredients	Working Range	Optimal Concentration
Methanol or Ethanol	0 to 30%	16%
Sodium Dodecyl Sulphate	5 to 30%	15%
25 Bovine Serum Albumin	0 to 5%	0.1%

04 Oct 2006

2002226643

- 9a -

This buffer is made up to the required volume, stirring in 0.1M TRIS/HCL Buffer, final pH of 8.0 \pm 1.

Differential Buffer:

5

Ingredients	Working Range	Optimal Concentration
Proteinase K	0.05 to 4mg/ml	0.4mg/ml

This buffer is made up to the required concentration in 0.1M TRIS/HCL Buffer, final pH of 8.0 \pm 1.

10

Assay Priming Buffer:

Ingredients	Working Range	Optimal Concentration
Guanidine	0.5 to 6M	3M
Sodium Hydroxide	0 to 0.5M	0.15M

OR

Ingredients	Working Range	Optimal Concentration
Urea	2 to 8M	6M
Sodium Hydroxide	0 to 0.5M	0.15M

5

This buffer is made up to the required concentration in reverse osmosis distilled water and allowed to reach room temperature before checking the pH, which should be greater than 11.

10 **Wash Buffer1:**

Ingredients	Working Range	Optimal Concentration
Sodium Chloride	0 to 10%	5%

This buffer is made up to the required volume in reverse osmosis distilled water, pH irrelevant.

15 **Wash Buffer 2:**

Ingredients	Working Range	Optimal Concentration
Phosphate Buffered Saline	0 to 5M	0.1M
Tween 20	0 to 5%	0.5%

This buffer is made up to the required volume in reverse osmosis distilled water, with a pH of 7.6 ± 1 .

20 The invention further provides a buffer selected from:

1. 0 to 20% of C₂ to C₅ alcohol, 15 to 30% sodium dodecyl sulphate, or 5 to 30% sodium dodcyl sulphate and 0 to 5% Sarcosyl, 0 to 0.5% bovine serum albumin and made up to volume in about 0.1M TRIS or phosphate buffer, the buffer having a final pH of 7.0 to 9.0;
- 5 2. A buffer comprising 1 to 10 mg/ml of a broad spectrum protease enzyme in about 0.1M TRIS or phosphate buffer with a final pH of 7.5 to 8.5;
3. A buffer comprising either 0.5 to 3M Guanidine or 2 to 8M urea, and 0.1 to 0.2M sodium hydroxide made up in reverse osmosis distilled water, with a pH of at least 11 at room temperature.

10

The invention will now be described in greater detail with reference to the following example.

EXAMPLE

15

The requirements for the TSE immunoassay are as follows:

- a) A sample of solid tissue, blood or blood derived preparation.
 - b) A series of preparative sample treatments.
 - 20 c) A prion specific antibody.
 - d) Sensitive method of detection.
- a) A sample of blood is taken using either an anti-coagulant coated tube or a non-coated blood tube. Two options are available for testing:
 - 25 i) Whole blood sample.
 - ii) A blood derived sample - serum sample or a buffycoat (white blood cells, leucocytes etc.) preparation.

A sample of solid tissue is taken from an animal or human by a suitable method e.g. biopsy or dissection.
 - 30 b) On reaching the laboratory the sample is identified using barcodes. The barcode assigned to each sample incorporates information on the place of origin of the sample

(slaughter plant, clinic, hospital), the date the sample is taken and a traceable identification sample number. An amount of each sample, is removed, weighed and placed into a sample bottle/tube/stomacher bag for homogenisation (stomaching, sonication or vortexing). If the sample is particularly gelatinous, an enzymatic degradation step can be included - addition of DNase, Rnase, protease or lipase used in accordance with supplier instructions. This sample bottle or bag containing the homogenised original sample will be assigned an identical barcode to the original sample. This allows full traceability throughout the system. A fixed volume to weight ratio (1:1 to 1:25) of Homogenising Buffer, supplied by Enfer Products, Castleblake, Rosegreen, Cashel, Co. Tipperary, is added to the sample bottle and the sample homogenised by stomaching, vortexing or sonication. If the sample is particularly gelatinous, an enzymatic degradation step can be included -addition of DNase, Rnase, protease or lipase used in accordance with supplier instructions. The sample is then dispensed (200 μ l) in duplicate onto a polypropylene 96 well microtitre plate. Blank, Negative and Positive controls supplied by Veterinary Research Laboratories, Abbotstown, Dublin are also added to this plate. This plate is centrifuged in a plate centrifuging rotor at 4000 rpm for 10 minutes. 20ul of Differential Buffer, supplied by Enfer Scientific, Castleblake, Rosegreen, Cashel, Co. Tipperary, is added preferably to a plastic, totally inert microtitre plate (e.g. DYNEX Microlite 1 plate made from immulon 1 plastic). The plate has to be inert for optimal completion of the assay. Use of charged plates decreases the results. 100 μ l of each of the centrifuged samples and controls is then transferred from the polypropylene centrifuged plate to the inert assay microlite plate containing the volume of Differential Buffer and a plate coverslip placed over the wells. The plate is then incubated at 37°C for 60 minutes, the coverslip removed and the plate washed in Wash Buffer 1, supplied by Enfer Scientific, Castleblake, Rosegreen, Cashel, Co. Tipperary. Assay priming Buffer, supplied by Enfer Scientific, Castleblake, Rosegreen, Cashel Co. Tipperary, is added to each well at a volume of 200 μ l. The plate is covered with a coverslip and incubated at 37°C for 15 minutes. The coverslip is removed on completion of the incubation and washed with Wash Buffer 2, supplied by Enfer Scientific, Castleblake, Rosegreen, Cashel Co. Tipperary, is then added to the samples on the plate. This step completes the sample preparation procedure.

c) The samples are now ready for immunoassay. This requires a prion specific antibody. An example for such an antibody is a rabbit anti - PrP, raised by injecting rabbits with ovalbumin conjugated synthetic prion peptides, a peptide which is licenced to Enfer Scientific by Proteus International UK. This peptide was identified by Proteus International UK using molecular modelling techniques followed by Western Blot and ELISA analysis. The peptides are synthesised in bulk using solid-phase peptide synthesis. Use of other anti-PrP antibodies raised to a variety of species - specific prion sequences in any species, will also yield satisfactory results in this assay. The peptide described herein is only one example of an antibody that has been successful in the assay. Both polyclonal and monoclonal antibodies can be used for assay. A fixed volume (150 μ l) of this specific antibody at optimal working strength dilution in Wash Buffer 2 is added to the microlite plate, incubated at 37°C for 40 minutes and washed using Wash Buffer 2. A fixed volume (150 μ l) of species-anti-rabbit(species)-HRP supplied by DAKO, USA at optimal working strength dilution in Wash Buffer 2 is added to the plate, incubated at 37°C for 30 minutes and washed using Wash Buffer 2. Detection of results is now possible.

d) Detection of results is by means of Enhanced Chemiluminescence. A fixed volume of a chemiluminescent reagent- Amerlite reagent (150 μ l) supplied by Johnson & Johnson, UK, is added to the microtitre plate and incubated at 37°C for 3 minutes. The light signal is read using a Labsystems Chemiluminometer, the results assigned to the corresponding barcode and a results report printed.

DETAILED PREPARATIVE PROTOCOL

25

1. HOMOGENISATION

1.1 Blood or blood derived or tissue sample is placed into a sample bottle/tube/bag.

1.2 1 to 25, preferably 10 to 15 times the sample weight of Homogenising Buffer is added to the sample.

30 1.3 This mixture is homogenised (stomacher, sonicator, vortex) for 2 minutes or until the sample is totally homogenised.

1.4 Enzymatic degradation option may be applied here at the discretion of the operator.

1.5 The resultant homogenate may be filtered, if particulate matter remains in the sample.

2. PLATING

- 5 2.1 A V-96-well microtitre polypropylene plate is used for centrifugation of 200 μ l of each sample.
- 2.2 200 μ l of blank control, onto the plate, positions A1,2 of the centrifuge plate.
- 2.3 200 μ l of negative control (known negative BSE homogenate), supplied by the Veterinary Research Laboratories, Abbotstown, Castleknock, Dublin, Ireland is
- 10 dispensed - 4 replicates- onto the plate, positions B1,2 and C1,2.
- 2.5 200 μ l of positive control, (known positive BSE homogenate), supplied by the Veterinary Research Laboratories, Abbotstown, Castleknock, Dublin, Ireland is
- dispensed - 4 replicates- onto the plate, positions D1,2 and E1,2.
- 2.6 200 μ l of each (filtered, enzymatically treated) homogenate is dispensed in
- 15 duplicate onto the plate, into the remaining positions.
- 2.7 The plate is centrifuged at 4000rpm for 10 minutes.
- 2.8 20 μ l of Differential Buffer is added to each well of an inert assay microtitre plate e.g. a DYNEX microlite 1 plate.
- 2.9 100 μ l of each centrifuged sample and control is removed from the centrifuge
- 20 plate and dispensed onto the same position on the inert assay microlite plate, bringing the well volume to 120 μ l.
- 2.10 The plate is covered with a microtitre plate sealer and incubated at 37°C for 60 minutes.
- 2.11 The plate is then washed 4 times with Wash Buffer 1.
- 25 2.11 200 μ l of Assay priming Buffer supplied by Enfer Products, Castleblake, Rosegreen Cashel, Co. Tipperary, Ireland, are added to each well of the microtitre plate and the plate incubated for 15 minutes at 37°C.
- 2.12 The plate is washed 4 times with Wash Buffer 2.
- 30 3. IMMUNOASSAY
- 3.1 150 μ l of primary antibody, rabbit (species) anti-PrP, polyclonal/monoclonal antibody at optimal dilution is dispensed onto the plate.

15

- 3.2 The plate is incubated at 37°C for 40 minutes.
- 3.3 The plate is washed 4 times with Wash Buffer 2.
- 3.4 150µl of secondary antibody, species-anti-rabbit(species)-HRP at optimal dilution is dispensed onto the plate and the plate incubated at 37°C for 30 minutes. Optimal dilution is determined by a grid assay e.g. plotting varying concentrations of primary and secondary antibody to determine optimal light signal (see below).
- 3.5 The plate is washed 4 times with Wash Buffer 2.

4. DETECTION

- 4.1 150µl of an enhanced chemiluminescent reagent-Amerlite reagent, supplied by Johnson & Johnson Clinical Diagnostics, UK is added to the plate.
- 4.2 The plate is incubated at 37°C for 3 minutes.
- 4.3 The light signal is read using a Labsystems Chemiluminometer, supplied by Medical Supply Company, Dublin, Ireland, which reads the luminescence from each well of the plate by scanning the entire IR-Visible-W spectra and extrapolating results.
- 4.4 The light signals from the plate are transferred to a customised software package, designed by G.K.S. Software, Dublin Ireland.
- 4.5 Each light signal is assigned to a corresponding bar-code and a report printed.
- 4.6 Results are quoted in chemiluminescent light units - L.U.

20

SOURCE OF REAGENTS

1. Prion Specific Antibodies - anti-PrP- are supplied by Enfer Scientific Ltd. and are polyclonal antibodies raised to the following synthetic prion peptide:

25 PRION SEQUENCE

N-TERM -

- MVKSHIGSWILVLFVAMWSDVGLCKKRPKPGGGWNTGGSRYPGQ- 44
- 30 GSPGGNRYPPQGGGGWGQPHGGGWGQPHGGGWGQPHGGGWGQP-87
- GGGGWGQGGSHSQWNKPSKPPKTNMKHVAGAAAAGAVVGGGLGGY- 131
- MLGSAMSSPLIHFQNDYEDRYTRENMYRYPNQVYYRPVDRYSNQNN-177

Single Letter Amino Acid Code:

A -Alanine, C- Cysteine, D -AsparticAcid, E- GlutamicAcid, F- Phenylalanine, G-
 5 Glycine, H - Histidine, I - Isoleucine, K - Lysine, L - Leucine, M- Methionine,
 N-Asparagine, P - Proline, Q - Glutamine, R -Arginine, S- Serine, T- Threonine, V-
 Valine, W- Tryptophan, Y- Tyrosine.

This 29 amino acid peptide is used to satisfactorily raise anti-PrP antibodies for the
 10 ELISA technique. This sequence was identified by Proteus International UK, using
 molecular techniques, as being a potentially useful peptide for production of anti-PrP
 antibodies that could be used successfully for TSE detection. The highlighted sequence
 is used to raise rabbit anti-PrP antibodies. The peptide (polypeptide, protein) is
 conjugated to activated ovalbumin, BSA or KLH and injected intra-muscularly or
 15 sub-cutaneously in Freund's Complete Adjuvant. Booster injections are sub-cutaneous
 and Freund's Incomplete Adjuvant is used. The rabbits are bled at 30 and 50 days post
 immunisation, or until a satisfactory titre is reached. Monoclonal antibodies can then be
 produced if required.

20

2. Enfer Buffers 1-3 are produced and supplied by Enfer Scientific.

Homogenising Buffer 1: 16% Methanol/Ethanol
 15 % Sodium Dodecyl Sulphate
 25 0.1% Bovine Serum Albumin

The buffer is made up to the required volume, stirring in 0.1M TRIS/HCL Buffer, final
 pH of 8.0±0.1. This buffer is stored from 16-25°C with an expiry of 1 year.

30 Differential Buffer 2: Proteinase K

Negative and positive controls are put in duplicate into every second set of wells. A series of antibody dilutions are made up 1/500 to 1/2000 as shown in Table 1 and the test is run. At the primary antibody addition stage the dilutions of primary antibody are put onto the negative and positive sample wells. At the end of the test the antibody concentration which gives the highest positive control value, without giving a high negative control result is used.

Table 1

Primary Antibody Conc.		1	2	3	4	5	6	7	8	9	10	11	12
1/500	A	Neg											
	B	Pos											
1/1000	C	Neg											
	D	Pos											
1/1500	E	Neg											
	F	Pos											
1/2000	G	Neg											
	H	Pos											

10

Example 2

The antibody optimisation assay is carried out as follows: positive and negative tissue, confirmed by the Veterinary Research Laboratory is used. This is the same material used for controls in the assay.

The tissue is diluted 1/15 in Homocnising buffer and homogenised for 2 minutes. 200ul of negative homogenate is then placed in rows A, C, E and G. 200ul of positive homogenate is placed in rows B, D, F and H. The plate is centrifuged for 10 mins at 400 rpm.

20ul of differential buffer is added to the assay plate and 100ul of each sample is transferred to corresponding wells.

The plate is then sealed and incubated for 1 hour at 37°C,

The plate is washed with wash buffer 1 and 200ul of primary buffer is added. This is
5 incubated for 15 minutes at 37°C.

A series of antibody solutions are made up in wash buffer 2, i.e. 1/500, 1/1000, 1/1500 and 1/2000, if the antibody has a higher titre or lower titre than this range a higher or extended range can be tried after the initial assay.

10

Following incubation in priming buffer the plate is washed with wash buffer 2.

150ul of each antibody concentration is then added to the appropriate wells and incubated for 40 minutes at 37°C. The plate is washed with wash buffer 2 and 150ul of secondary antibody is added to all wells for 30 minutes at 37°C and then the plate is
15 washed again with wash buffer 2 and 150ul of chemiluminescence substrate is added to all wells. After a 3 minute incubation at 37°C the wells are read the chemiluminometer.

The antibody concentration which gives the best result i.e. low negative preferably <1.0, while giving a good positive result eg 500 is the concentration chosen.

20

As mentioned earlier a higher dilution range can be selected before the antibody is used, but this assay gives a good idea whether or not the antibody can be used.

1/500	{	N	4.235	3.897	3.554	4.116	2.698	3.487	4.679	3.229	4.569	3.487	3.778	4.946
	{	P	724.5	759.4	811.6	792.4	772.5	851.3	764.2	844.2	793.4	882.4	816.7	799.2
1/100	{	N	2.987	2.897	2.378	2.556	2.446	2.791	3.016	1.945	2.069	2.449	2.164	2.310
	{	P	563.4	547.2	538.0	587.1	564.2	603.7	589.4	556.1	567.3	613.7	508.6	543.7
1/500	{	N	1.579	0.945	1.344	1.067	1.337	1.298	1.049	0.879	1.346	1.222	1.340	1.206
	{	P	457.6	476.5	503.0	402.1	449.5	432.8	463.7	433.0	492.7	409.7	430.9	443.1
1/2000	{	N	0.861	0.936	0.727	0.914	0.866	0.569	0.612	0.493	0.721	0.642	0.463	0.762
	{	P	366.9	322.3	390.1	377.5	376.1	349.4	346.7	334.8	329.4	367.4	329.4	337.9

Example 3

Experimental Data on the suitability of the Enfer TSE assay as a means of detecting TSE in different tissues, namely, central nervous tissues (CNS), lymph tissue and blood and in different species, ovine and bovine.

Results of routine testing using the TSE Assay of the invention in 2001.**Bovine CNS tissue**

10 Total samples tested : 664942
 No. of positives detected : 134
 No. of positives confirmed : 134
 by immunohistochemistry

Ovine CNS tissue

15 Total samples tested : 16467
 No. of positives detected : 60
 No. of positives confirmed : 60
 by immunohistochemistry

20

Ovine Lymph tissue

Total samples tested : 6974
 No. of positives detected : 10
 Confirmed : 9*
 25 by immunohistochemistry

It was not possible to confirm one lymph tissue sample. This tissue was from a 14 week old lamb and was in the very early stages of infection. This may explain the difficulties with confirmation.

30

2002226643 04 Oct 2006

WO 02/057789

PCT/TE02/00006

22

Ovine Blood tissue (1998)

Total tested : 3
No. of positives : 3

5 This was fresh blood derived from clinical Scrapie cases. All cases were found to be weakly positive and no confirmatory method exists to do a follow up analysis.

10 Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers or steps but not the exclusion of any other integer or group of integers or steps.

15 The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

20

25

30

2002226643 04 Oct 2006

- 23 -

The claims defining the invention are as follows:

1. A method of detecting TSE comprising (a) dispensing a sample of tissue, blood or a blood derivative from a test subject onto an inert support and treating the sample with a
5 homogenization buffer comprising alcohol in an amount up to 30% and between 5% and 30% detergent, (b) adding an agent which degrades normal prion protein, (c) adding an agent which denatures abnormal prion protein, (d) adding a prion-specific antibody, and (e) detecting binding of the antibody to the sample.
- 10 2. The method as claimed in claim 1 wherein step (a) further comprises the addition of a protein.
3. The method as claimed in claim 2 wherein the protein is a high molecular weight protein, selected from the group consisting of bovine serum albumin, ovalbumin, normal
15 serum of animal origin, and an albumin substitute.
4. The method as claimed in claim 2 or 3 wherein the protein is formulated in a buffer containing up to 5% protein.
- 20 5. The method as claimed in claim 4 wherein the protein is formulated in a buffer containing 0.05 to 0.4% protein.
6. The method as claimed in any one of the preceding claims wherein the alcohol used in step (a) is a C₁ to C₂₄ alcohol.
25
7. The method as claimed in claim 6 wherein the alcohol used in step (a) is a C₁ to C₅ alcohol.
8. The method as claimed in claim 6 wherein the alcohol is selected from methanol,
30 ethanol, propanol, butanol, pentanol, hexanol, heptanol, octanol, nonanol, decanol, undecanol, dodecanol, tridecanol, pantadecanol, cetyl alcohol, heptadecanol, stearyl

2002226643 04 Oct 2006

- 24 -

alcohol, nonadecanol, eicosanol, docasanol, dodecyl alcohol, lauryl alcohol, octadecanol.

9. The method as claimed in claim 6 wherein the alcohol is methanol or ethanol.
- 5 10. The method as claimed in any one of the preceding claims wherein the alcohol is formulated in a buffer containing 10% to 20% (by weight) alcohol.
11. The method as claimed in claim 10 wherein the alcohol is formulated in a buffer containing 8% to 12% alcohol.
- 10 12. The method as claimed in any one of the preceding claims wherein the detergent of step (a) is selected from sodium dodecyl sulphate, sarcosyl, lithium dodecyl sulphate, cholic acid, deoxycholic acid, Triton X-100, octanoic acid, 30% aqueous solution of polyoxyethylene (23) Lauryl Ether (Brij 35 solution), N-Cetyl-N,N,N-trimethylammoniumbromide, CHAPS, CHAPSO, Digitonin, nonanoyl-N-methylglucamide, n-Octyl-B-D-glucopyranoside, alkyl sodium sulphate, dioctyl sodium sulfosuccinate, sodium oleate, sodium lauryl sulphate, 1,2,3-Octanetriol, 3-Diethylamino-1 propyne, Chondroitinase ABC, sodium Ionophore 1.
- 15 13. The method as claimed in any one of the preceding claims wherein the detergent of step (a) is sodium dodecyl sulphate.
- 20 14. The method as claimed in any one of the preceding claims wherein the homogenization buffer contains 10 to 20% detergent.
- 25 15. The method as claimed in any one of claims 12 or 14 wherein the homogenization buffer contains 16% detergent.
- 30 16. The method as claimed in any one of the preceding claims wherein in step (b) the agent which degrades normal prion protein is a protease.

04 Oct 2006
2002226643

- 25 -

17. The method as claimed in claim 16 wherein the protease is a broad spectrum protease.
- 18: The method as claimed in claim 17 wherein the protease is selected from
5 proteinase K, subtilisin Carlsberg and pepsin.
19. The method as claimed in any one of claims 16 to 18 wherein the protease is formulated in a buffer containing up to 10mg/ml protein.
- 10 20. The method as claimed in claim 19 wherein the buffer contains 0.05 mg/ml to 4 mg/ml protein.
21. The method as claimed in claim 19 wherein the buffer contains 0.2 mg/ml to 0.6 mg/ml protein.
- 15 22. The method as claimed in any one of the preceding claims wherein the agent which denatures abnormal prion protein in step (c) is a denaturing salt solution.
23. The method as claimed in claim 22 wherein the agent is selected from guanidine,
20 urea, and a standard denaturing solution.
24. The method as claimed in any one of the preceding claims wherein the denaturing agent further includes up to 0.5M sodium hydroxide.
- 25 25. The method as claimed in any one of the preceding claims wherein the denaturing salt is formulated in a buffer containing 0.1 to 10M denaturing salt.
26. The method as claimed in claim 25 wherein the denaturing salt is formulated in a
buffer containing 2M to 8M denaturing salt.
30

04 Oct 2006
2002226643

- 26 -

27. The method as claimed in any one of the preceding claims wherein the buffer of step (a) (homogenising buffer) is made up to have a final pH of 5.0 to 11.0.
28. The method as claimed in claim 27 wherein the buffer of step (a) is made up to have a final pH of 7.0 to 9.0.
29. The method as claimed in claim 27 wherein the buffer of step (a) is made up to have a final pH of 7.5 to 8.5.
30. The method as claimed in any one of the preceding claims wherein the buffer of step (b) (differential buffer) is made up to a final pH of 2.0 to 11.0.
31. The method as claimed in claim 30 wherein the buffer of step (b) is made up to a final pH of 2.0 to 8.5.
32. The method as claimed in claim 30 wherein the buffer of step (b) is made up to have a final pH of 7.5 to 8.5.
33. The method as claimed in any one of the preceding claims wherein the buffer of step (c) (assay priming buffer) has a pH of 1 to 14.
34. The method as claimed in claim 33 wherein the buffer of step (c) has a pH of 9 to 12.
35. The method as claimed in claim 33 wherein the buffer of step (c) has a pH of at least 11.
36. The method as claimed in any one of the preceding claims wherein following step (b) the reaction mixture is washed with a first wash buffer comprising up to 10% buffered solution.

P:\PRODCEN\ADMIN\pat7254031 new el.doc final.doc-26796

2002226643 18 Oct 2006

- 27 -

37. The method as claimed in claim 36 wherein the first wash buffer comprises 4 to 6% buffered solution.
38. The method as claimed in any one of the preceding claims wherein the assay priming buffer is allowed to incubate with the reaction mixture for about 5 to 30 minutes.
39. The method as claimed in claim 38 wherein the assay priming buffer is allowed to incubate with the reaction mixture for 10 to 20 minutes.
40. The method as claimed in any one of the preceding claims wherein after treatment with the assay priming buffer the mixture is washed with a second wash buffer having a final pH of 5.0 to 11.0.
41. The method as claimed in claim 40 wherein the second wash buffer has a final pH of 7.0 to 8.0.
42. The method as claimed in claim 36 wherein the first wash buffer comprises sodium chloride, calcium chloride, and/or zinc chloride.
43. The method as claimed in claim 40 wherein the second wash buffer comprises phosphate buffered saline with the optional addition of 0 to 5% Tween 20.
44. The method as claimed in any one of the preceding claims wherein the blood or tissue sample is dispensed onto a support, suitably a microtitre tray.
45. The method as claimed in any one of the preceding claims wherein the prion specific antibody is raised to a prion sequence which is to the 5' side of amino-acid number 60 of the prion sequence.
46. The method as claimed in any one of the preceding claims comprising reacting a sample of blood or a blood derivative or tissue obtained from a test subject with a prion

2002226643 04 Oct 2006

- 28 -

specific antibody and detecting the binding of the antibody to the sample by standard immunoassay, wherein the tissue, blood or blood derivative sample is mixed prior to addition of the antibody with a first buffer comprising 0 to 30% of C₁ to C₅ alcohol, 5 to 30% sodium dodecyl sulphate, or 5 to 30% sodium dodecyl sulphate and 0 to 5% sarcosyl, and 0 to 5% bovine serum albumin made up to volume in about 0.1 M TRIS/HCL or phosphate buffer, the buffer having a final pH of 7.0 to 9.0.

47. A test for Transmissible Spongiform Encephalopathies comprising homogenizing a sample of blood or blood derivative or tissue obtained from a test subject in a homogenization buffer comprising alcohol in an amount up to 30% and between 5% and 30% detergent, reacting the tissue, blood or blood derivative sample with a prion specific antibody and detecting the binding of the antibody to the sample by standard immunoassay, wherein the blood or tissue sample is dispensed onto an inert support and incubated with a buffer comprising up to 10 mg/ml of a broad spectrum protease enzyme in a buffer with a final pH of 2.0 to 11.0 prior to reaction with the antibody.

48. A test for Transmissible Spongiform Encephalopathies comprising homogenizing a sample of blood or a blood derivative or tissue obtained from a test subject in a homogenization buffer comprising alcohol in an amount up to 30% and between 5% and 30% detergent, reacting the tissue, blood or blood derivative sample with a prion specific antibody and detecting the binding of the antibody to the sample by standard immunoassay, wherein the sample is incubated with a buffer comprising 0.1 to 10M denaturing solution, preferably 3 to 6M Guanidine or 2 to 8M urea, and up to 0.5M sodium hydroxide made up in reverse osmosis distilled water, with a pH of at least 11 at room temperature, prior to reaction with the antibody.

2002226643 04 Oct 2006

- 29 -

49. A test for Transmissible Spongiform Encephalopathies and/or a method of detecting TSE substantially as herein described with reference to Example 1 and Example 2.

5 DATED this 27th day of September, 2006

ENFER TECHNOLOGY LIMITED

by its Patent Attorneys

DAVIES COLLISON CAVE

10

15